A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
We report the case of a 78-year-old man diagnosed with metastatic renal cell carcinoma developping acute haemolysis under Sunitinib as well as under Sorafenib. This side effect induced a definitive withdrawal from the drugs. As these drugs are used more widely, rare side effects are bound to appear.
Berchem
Guy
G
Service d'Hémato-Cancérologie, Centre Hospitalier de Luxembourg, 4, rue Barblé, L-1210 Luxembourg. berchem.guy@chl.lu
Dewilde
Sigrid
S
Mahassen
Philippe
P
D000368:Aged; D000743:Anemia, Hemolytic / Q000139:chemically induced*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001557:Benzenesulfonates / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006454:Hemoglobins / Q000378:metabolism; D006461:Hemolysis; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D011758:Pyrroles / Q000009:adverse effects*; D000077157:Sorafenib; D000077210:Sunitinib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D006454:Hemoglobins; D007211:Indoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D007770:L-Lactate Dehydrogenase; D000077210:Sunitinib